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ABSTRACT
Aims Premature cardiovascular events complicate
chronic inﬂammatory conditions. Low-dose weekly
methotrexate (MTX), the most widely used disease-
modifying drug for rheumatoid arthritis (RA), reduces
disease-associated cardiovascular mortality. MTX
increases intracellular accumulation of adenosine
monophosphate (AMP) and 5-aminoimidazole-4-
carboxamide ribonucleotide which activates AMP-
activated protein kinase (AMPK). We hypothesised that
MTX speciﬁcally protects the vascular endothelium
against inﬂammatory injury via induction of AMPK-
regulated protective genes.
Methods/results In the (NZW×BXSB)F1 murine model
of inﬂammatory vasculopathy, MTX 1 mg/kg/week
signiﬁcantly reduced intramyocardial vasculopathy and
attenuated end-organ damage. Studies of human
umbilical vein endothelial cells (HUVEC) and arterial
endothelial cells (HAEC) showed that therapeutically
relevant concentrations of MTX phosphorylate
AMPKαThr172, and induce cytoprotective genes including
manganese superoxide dismutase (MnSOD) and haem
oxygenase-1 (HO-1). These responses were preserved
when HUVECs were pretreated with tumour necrosis
factor-α to mimic dysfunctional endothelium.
Furthermore, MTX protected against glucose deprivation-
induced endothelial apoptosis. Mechanistically, MTX
treatment led to cyclic AMP response element-binding
protein (CREB)Ser133 phosphorylation, while AMPK
depletion attenuated this response and the induction of
MnSOD and HO-1. CREB siRNA inhibited upregulation
of both cytoprotective genes by MTX, while chromatin
immunoprecipitation demonstrated CREB binding to the
MnSOD promoter in MTX-treated EC. Likewise,
treatment of (NZW×BXSB)F1 mice with MTX enhanced
AMPKαThr172 phosphorylation and MnSOD, and reduced
aortic intercellular adhesion molecule-1 expression.
Conclusions These data suggest that MTX
therapeutically conditions vascular endothelium via
activation of AMPK-CREB. We propose that this
mechanism contributes to the protection against
cardiovascular events seen in patients with RA treated
with MTX.
INTRODUCTION
Premature cardiovascular disease (CVD) is a serious
long-term complication of chronic systemic inﬂam-
matory diseases including rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE). Despite
advances in disease-modifying and biological
therapy for these diseases, we lack speciﬁc strategies
aimed at retarding development of premature CVD
and have limited knowledge of whether individual
drugs offer vascular protection. Since endothelial
dysfunction precedes overt atherosclerosis, investi-
gating the ability of drugs to activate cytoprotective
signalling pathways that prevent or reverse endo-
thelial dysfunction is an attractive research strategy.
Cytoprotective pathways include those regulated by
AMP-activated kinase (AMPK). AMPK, a ubiqui-
tous signalling kinase composed of a heterotrimeric
complex of a catalytic α subunit and regulatory
β and γ subunits, is generally considered a sensor of
cellular metabolic status.1 In endothelial cells (EC),
AMPK activity exerts multiple protective effects
including enhanced endothelial nitric oxide syn-
thase phosphorylation and nitric oxide synthesis,2
mitochondrial biogenesis,3 and protection against
apoptosis4 and oxidative damage.5 6
Methotrexate (MTX) therapy is central to the
current treatment paradigms for RA. There is sound
evidence that MTX reduces CVD in RA7 8 and
improves clinical markers of endothelial dysfunc-
tion.9 These ﬁndings led to the recently initiated
Cardiovascular Inﬂammation Reduction Trial, in
which MTX or placebo is prescribed to patients
with prior myocardial infarction (MI) to test the
inﬂammatory hypothesis of atherothrombosis:10 an
intriguing new direction in the treatment of CVD.
Mechanistic understanding of the vasculoprotec-
tive actions of MTX is sparse. However, it is
known that long-lasting polyglutamate metabolites
of MTX inhibit 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) transformylase and adeno-
sine deaminase, leading to a rise in intracellular
concentrations of AICAR-monophosphate (ZMP)
and AMP.11 The subsequent accumulation and
extracellular release of adenosine has been pro-
posed as the principal anti-inﬂammatory mechan-
ism of action of MTX.12 13 However, both ZMP
and AMP are AMPK activators. We, therefore,
hypothesised that the low-dose MTX regimen used
in contemporary rheumatology practice activates
AMPK, leading to enhanced expression of cytopro-
tective proteins within vascular EC: a new mechan-
ism of action to explain its clinical action in
reducing CVD associated with inﬂammation.
MATERIALS AND METHODS
Detailed methods are supplied in the online supple-
mentary ﬁle.
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(NZW×BXSB)F1 (WBF1) male mice were bred from female
New Zealand White (Harlan, UK) and male BXSB mice (bred
in-house). They were studied according to UK Home Ofﬁce
guidelines and with ethical approval from Imperial College
(Licence PPL 70/6722). Animals were treated from 12 to
16 weeks with MTX 1 mg/kg (TEVA, UK) or an equal volume
of 0.9% saline by weekly intraperitoneal injection. After euthan-
asia, the heart was parafﬁn-embedded and sections stained with
periodic acid-Schiff (PAS) or picrosirius red for analysis of the
vascular disease or myocardial infarct size. The aorta was snap-
frozen, sectioned transversely or ground and analysed by
immunoﬂuorescence or immunoblotting.
Human umbilical vein EC (HUVEC) and human aortic EC
(HAEC) were treated for up to 72 h with MTX 0.1–100 nM
before analysis by immunoblotting, quantitative real-time PCR,
ﬂow cytometry and chromatin immunoprecipitation.
RESULTS
MTX reduces the severity of intramyocardial vasculopathy
and attenuates organ damage in WBF1 mice
To demonstrate the vasculoprotective properties of low-dose
MTX in vivo, (NZW×BXSB)F1 (WBF1) mice were studied.
WBF1 mice develop SLE, characterised by glomerulonephritis,
anti-DNA and antiphospholipid antibodies.14 15 A high propor-
tion (up to 80%) develop vasculopathy of the muscular
intramyocardial arteries.16 Pathological features include an
adventitial inﬂammatory cell inﬁltrate, deposition of
PAS-positive immunoglobulin and complement within the arter-
ial wall, and progression to arterial occlusion and MI.17
WBF1 mice were treated with MTX 1 mg/kg by weekly intra-
peritoneal injection for 4 weeks from 12 to 16 weeks of age.
The dose of MTX chosen is representative of long-term
low-dose MTX therapy used to treat inﬂammatory diseases clin-
ically, and falls between those concentrations shown to increase
adenosine levels and protect against collagen-induced arth-
ritis.13 18 At 12 weeks, disease is detectable in WBF1 mice,16
thus, intervention was timed to model the treatment of early
systemic inﬂammatory disease in patients and to demonstrate
reversibility of the vasculopathy.
Following 4 weeks treatment with MTX, a signiﬁcant reduc-
tion in the intramyocardial vasculopathy was observed. This was
quantiﬁed by ﬁrst counting inﬁltrating leucocytes in the adventi-
tia of each intramyocardial artery in a single section per animal
(ﬁgure 1A–C); and second, by scoring the deposition of
PAS-positive material in arterial walls (ﬁgure 1D–F).
Furthermore, MTX reduced end-organ damage in WBF1
mice. A multisystem organ damage score (see online supplemen-
tary table) used postmortem demonstrated a signiﬁcant protect-
ive effect of MTX (ﬁgure 1G). Speciﬁcally relating to cardiac
disease, at 16 weeks, 41% of untreated mice in our cohort had
an MI consistent with previous reports in this model at this time
point (ﬁgure 1H).16 19 Although the optimal time to identify an
effect of MTX on infarct incidence would be at 24–30 weeks,
when the frequency of MI is 53%–62%, data would be con-
founded by the onset of disease-related renal impairment and
consequent increased MTX toxicity. Thus, although not reach-
ing statistical signiﬁcance at the earlier 16-week time-point,
fewer MTX-treated mice suffered an MI (21% vs 41% in the
untreated animals), with infarcts smaller in the treated mice
(ﬁgure 1H–K).
Thus, low-dose MTX reduces inﬂammatory vascular injury in
vivo, leading to a reduction in end-organ damage in WBF1
mice.
MTX phosphorylates AMPK and induces MnSOD and other
cytoprotective target genes
To identify potential mechanisms underpinning vascular pro-
tection, we investigated the hypothesis that, through its effects
on nucleotide metabolism, MTX may activate AMPK, a signal-
ling kinase with signiﬁcant vascular protective actions, includ-
ing manganese superoxide dismutase (MnSOD) induction.20
MnSOD is a mitochondrial antioxidant enzyme that catalyses
the conversion of superoxide into hydrogen peroxide.
Induction of MnSOD is an important vascular cytoprotective
response, capable of protecting against mitochondrial damage
and atherogenesis.21 To establish whether MTX activates
human endothelial AMPK, HUVECs were exposed to 100 nM
MTX for up to 72 h. The concentration chosen is able to
increase intracellular AICAR in vitro12 and is achievable in
patient plasma following conventional low-dose therapeutic
dosing.22 AMPKαThr172 phosphorylation was observed after
48 h treatment, but not earlier, in HUVEC (ﬁgure 2A, B; 24
and 72 h data not shown) and in HAECs (see online supple-
mentary ﬁgure IA, B). The delay in phosphorylation suggests
an indirect action, such as the accumulation of AICAR and
AMP following inhibition of AICAR transformylase by MTX
polyglutamate metabolites, rather than a direct action of MTX
on upstream AMPK-kinases.
In addition to AMPK phosphorylation, induction of MnSOD
mRNA and protein was seen after 48 h of MTX treatment. This
response was concentration-dependent, ﬁrst seen with MTX
0.1 nM and maximal at 10 and 100 nM (see ﬁgure 2C–E; time
course online supplementary ﬁgure IC) and reproducible in
HAECs (see online supplementary ﬁgure ID, E). Increased
MnSOD was also detected following AICAR treatment of
HUVECs (ﬁgure 2F, G), and has previously been linked with
AMPK activity.3 6 23 In addition to MnSOD, 48 h exposure to
low-dose MTX increased expression of other important endo-
thelial cytoprotective genes. These included the antioxidant,
anti-inﬂammatory, antiapoptotic enzyme haem oxygenase-1
(HO-1; ﬁgure 3A and online supplementary ﬁgure IF, G);
Bcl-2-related protein Al (A1), an antiapoptotic member of the
Bcl-2 family (ﬁgure 3B), and uncoupling protein-2 (UCP2),
important for regulation of mitochondrial-reactive oxygen
species generation (ﬁgure 3C). After 72 h, induction of the
complement-inhibitory protein decay-accelerating factor (DAF,
CD55) was also observed (ﬁgure 3D). Thus, MTX-mediated
AMPK activation in EC is linked to the regulation of a variety
of AMPK-dependent protective genes, all of which are
antiatherogenic.
MnSOD induction by MTX requires AMPK and CREB
activation
To dissect further, the transcriptional pathway involved in
MnSOD induction by MTX, cyclic AMP-response element
binding protein (CREB) was identiﬁed as a potential candidate.
CREB is a direct downstream target of AMPK,23 24 its activity is
positively associated with vascular health,25 and it has been
implicated in MnSOD induction.26 CREBSer133 phosphorylation
was observed following treatment of HUVEC with MTX
(ﬁgure 4A, B). In order to determine the role of AMPK, a
loss-of-function approach was adopted. HUVECs were trans-
fected with siRNA directed against the AMPKα1 or α2 subunit
(see online supplementary ﬁgure IIA, B), prior to MTX treat-
ment. MTX-mediated CREBSer133 phosphorylation was abro-
gated by AMPKα1 or α2 siRNA (ﬁgure 4A, B), suggesting a
linear signalling pathway between AMPK and CREB.
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Next, the same approach was used to establish whether
MnSOD induction by MTX is dependent upon AMPK activa-
tion. Induction of MnSOD mRNA and protein by MTX was
signiﬁcantly attenuated by AMPKα2 siRNA (ﬁgure 4A, C, D).
Similar results were obtained following depletion of AMPKα1
(ﬁgure 4A; quantiﬁcation data not shown). Likewise, analysis of
HO-1 expression showed that depletion of AMPKα1 or α2
inhibited MTX-mediated HO-1 induction (see online supple-
mentary ﬁgure IIC–E). Additionally, treatment of HUVECs with
Compound C, a pharmacological AMPK antagonist, signiﬁ-
cantly reduced induction of MnSOD and HO-1 mRNA by
MTX (see online supplementary ﬁgure IIF, G). Further investi-
gation demonstrated the functional role of CREB, with siRNA
depletion (see online supplementary ﬁgure IIIA, B) preventing
MnSOD and HO-1 induction by MTX (see ﬁgure 4E and
online supplementary ﬁgure IIIC).
Chromatin immunoprecipitation was performed to look for
enhanced CREB binding to the MnSOD promoter in HUVECs
Figure 1 Methotrexate (MTX) attenuates intramyocardial vasculopathy and reduces severity of organ damage in WBF1 mice. Male WBF1 mice
were treated with MTX 1 mg/kg (n=19) or an equal volume of 0.9% saline (n=18) by intraperitoneal injection weekly for 4 weeks from 12 to
16 weeks of age. Short-axis parafﬁn-embedded sections of heart were stained with periodic acid-Schiff (PAS) and picrosirius red. Vasculopathy was
quantiﬁed by counting cells inﬁltrating the adventitia of intramyocardial arteries and by scoring PAS-positive staining in the vessel walls, and
myocardial infarction (MI) area was quantiﬁed by picrosirius red staining. A disease-related damage score (see online supplementary table) was
constructed based on ﬁndings at postmortem. (A) An artery with a periadventitial leucocytic inﬁltrate (arrow), compared with normal artery (B) and
(C) quantiﬁcation of the mean number of adventitial cells per vessel. (D) Artery with severe thickening of the PAS-positive basement membrane
(arrow) and compared with normal artery (E) and (F) quantiﬁcation of the arterial vasculopathy score shows (G) the global damage score, (H) the
incidence of MI, and (I) quantiﬁcation of the total area of infarcted myocardium, quantiﬁed by picrosirius red staining of short-axis sections of heart.
(J) and (K) Representative photomicrographs of picrosirius red staining with ( J) extensive ﬁbrotic infarcts involving the right ventricle and septum
(arrows) in a saline-treated animal, and (K) a small ﬁbrotic infarct in the left ventricle epicardium of a MTX-treated animal (arrow). ns, not
statistically signiﬁcant; *p<0.05; ***p<0.001.
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treated with MTX. Analysis of the SOD2 promoter (GenBank
accession number AF059197) using MatInspector software
identiﬁed two strong potential CREB binding sites (see online
supplementary ﬁgure IV), the more proximal of which has pre-
viously been validated using a reporter assay and a series of
deletion constructs.26 Signiﬁcant enrichment of CREB binding
to the MnSOD promoter following MTX treatment was found
using primers designed to interrogate the known validated
binding site (ﬁgure 4F). No enhanced binding was seen with
primers designed around a negative control downstream region.
MnSOD and HO-1 induction by MTX is maintained when ECs
are treated with folic acid or TNFα
To determine whether the low-dose MTX-induced changes in
gene expression in quiescent ECs are relevant clinically, we
investigated responses in cells coadministered with folic acid
(FA), and those exposed to tumour necrosis factor α (TNFα) to
model an activated, dysfunctional endothelium.
FA is routinely prescribed alongside MTX to reduce side
effects. When HUVECs were treated with clinically relevant
concentrations of FA (50 nM)27 and MTX in combination, no
Figure 2 MTX treatment leads to AMPKα phosphorylation and induction of MnSOD mRNA and protein. (A) and (B) HUVEC were treated with MTX
100 nM for 48 h. AMPKα phosphorylation was demonstrated by immunoblot (A; with densitometry B), using AMPK agonist AICAR 1 mM as positive
control. HUVECs were treated with MTX 0–100 nM and (C) MnSOD mRNA, and (D) and (E) MnSOD protein were quantiﬁed after 48 h by qRT-PCR
and immunoblotting, respectively. (F) and (G) HUVEC were treated with AICAR for up to 48 h and MnSOD quantiﬁed by immunoblotting. Each
experiment was performed three to ﬁve times. A: AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK, AMP-activated protein kinase;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HUVEC, human umbilical vein endothelial cells; MnSOD, manganese superoxide dismutase;
MTX, methotrexate; UT, untreated. *p<0.05; **p<0.01.
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change in the magnitude of MnSOD induction was observed
(ﬁgure 5A).
Patients with RA and also those with primary coronary artery
disease develop endothelial dysfunction as an early feature.
TNFα is an important mediator and was chosen to model endo-
thelial dysfunction in vitro. ECs were exposed to TNFα 1 ng/
mL for 24 h prior to the addition of MTX for 48 h.
MTX-induced upregulation of MnSOD and HO-1 mRNA was
preserved (ﬁgure 5B, C). These ﬁndings conﬁrm the ability of
MTX to condition ECs in the face of a chronic proinﬂammatory
stimulus.
MTX protects against endothelial apoptosis induced by
glucose deprivation
Next, the cytoprotective actions of MTX were investigated. The
principal function of AMPK activation is to conserve energy; it
is, therefore, critically important in the cellular response to
glucose deprivation.1 4 We hypothesised that survival of ECs
exposed to a glucose-deﬁcient medium would be prolonged if
they were pretreated with MTX, as AMPK signalling would
already be active.
ECs were treated with MTX 100 nM for 48 h, and then main-
tained for 18 h in Hanks’ balanced salt solution (HBSS) or
glucose-deﬁcient HBSS. Early apoptosis was detected by Annexin
V staining, and established cell death by permeability to propi-
dium iodide (PI), using ﬂow-cytometric quantiﬁcation. Glucose
deprivation led to a marked increase in Annexin V binding to the
EC surface and doubling of PI-positive cells. These responses
were signiﬁcantly reduced by MTX (ﬁgure 5D–G). Moreover,
MTX did not increase EC apoptosis under normoglycemic con-
ditions, although there was a modest reduction in total cell
numbers consistent with impaired proliferation (see online sup-
plementary ﬁgure V). These data suggest that the primary effect
of MTX treatment on vascular EC is protective and that AMPK
activation and subsequent protective gene induction do not rep-
resent a stress response to a noxious stimulus.
MTX phosphorylates AMPK and increases MnSOD in murine
aortic tissue and reduces endothelial and adventitial
ICAM-1 expression
Finally, snap-frozen descending aortae harvested from the
MTX-treated and saline-treated animals described above were
used to analyse the effect of MTX therapy on the protective
pathways in vivo. Immunoblotting of WBF1 aortic lysates
revealed increased AMPKαThr172 phosphorylation and MnSOD
protein expression in MTX-treated animals (ﬁgure 6A–D).
Given that MTX is also a powerful anti-inﬂammatory agent,
it is likely that vascular protection induced by MTX is mediated,
at least in part, by anti-inﬂammatory actions. To assess this,
aortic intercellular adhesion molecule (ICAM)-1 expression was
quantiﬁed. Transverse aortic sections from MTX and saline-
treated WBF1 mice were stained with an antimouse ICAM-1
monoclonal antibody and examined by immunoﬂuorescence
confocal microscopy. MTX therapy reduced both endothelial
and adventitial ICAM-1 staining (ﬁgure 6E–H). The reduction
in adventitial staining is likely to be of particular relevance in
the amelioration of organ damage in this model, given the
reduction in the adventitial leucocytic inﬁltrate also observed in
the intramyocardial arteries (ﬁgure 1A–C).
DISCUSSION
The current study identiﬁes a novel MTX-activated protective
pathway which may underpin the ability of MTX to reduce
CVD associated with chronic inﬂammation. However, the his-
torical general perception of MTX is that it is harmful and clin-
ically effective only because it kills pathological tissue before
normal cells are irreversibly damaged. Indeed, early studies on
MTX and CVD in RA suggested CVD was increased.28
Figure 3 MTX treatment results in
the induction of AMPK target genes.
HUVEC were treated with MTX 100 nM
for 48 h and mRNA levels of (A) HO-1,
(B) A1, and (C) UCP-2 mRNA were
analysed by qRT-PCR. (D) Induction of
DAF mRNA was measured after 72 h
MTX treatment. Each graph represents
the results of four experiments. AMPK,
AMP-activated protein kinase; A1,
Bcl-2-related protein A1; DAF,
decay-accelerating factor; HO-1, haem
oxygenase-1; HUVEC, human umbilical
vein endothelial cells; MTX,
methotrexate; UCP-2, uncoupling
protein-2; UT, untreated. *p<0.05;
**p<0.01.
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Subsequent experience is, however, altering perceptions.
Several studies have demonstrated that long-term low-dose
MTX therapy in RA (15–20 mg/week) is associated with
reduced CVD, with Choi et al reporting a 70% reduction in car-
diovascular (CV) mortality.7 8 Likewise, MTX therapy reduced
atheroma in cholesterol-fed rabbits.29 These results might reﬂect
an antiatherogenic action of adenosine via ligation of its A2A
receptor which, in addition to an anti-inﬂammatory action, may
induce reverse cholesterol transport proteins and prevent foam
cell formation.30 However, our study supports an additional
mechanism, namely that MTX exerts a direct beneﬁcial effect
on vascular endothelium.
Patients with RA and SLE with normal epicardial coronary
arteries exhibit coronary microvascular dysfunction which may
precede and contribute to accelerated atherosclerosis.31 Thus, to
explore the arterioprotective actions of MTX, we investigated
WBF1 mice, which develop an inﬂammatory vasculopathy of
small muscular arteries and arterioles that predispose to throm-
bosis and tissue infarction. A previous attempt to treat WBF1
mice with MTX failed to show improvement in mortality or
Figure 4 Methotrexate (MTX) activates an AMP-activated protein kinase (AMPK) and cyclic AMP-response element binding protein (CREB) linear
signalling pathway to induce manganese superoxide dismutase (MnSOD). (A–D) AMPKα1 or AMPKα2 subunits were depleted in human umbilical
vein endothelial cells (HUVEC) by RNA interference, prior to addition of MTX (100 nM) for 48 h and analysis of: (A) MnSOD, CREBSer133
phosphorylation and total CREB by immunoblotting. (B) Densitometric quantiﬁcation of changes in CREB phosphorylation. Changes in (C) MnSOD
mRNA and (D) MnSOD protein. (E) HUVECs transfected with control or CREB siRNA were treated with MTX and MnSOD mRNA analysed by
qRT-PCR. (F) HUVECs were treated with MTX for 48 h for chromatin immunoprecipitation analysis of CREB binding of the MnSOD promoter.
Following immunoprecipitation with an anti-CREB monoclonal antibody or negative control immunoglobulin G (IgG), isolated chromatin was used in
a qRT-PCR reaction with primers spanning CREB binding sites within the MnSOD promoter and a downstream control site. Data is presented
normalised to input DNA and IgG control. α1, AMPKα1 siRNA; α1M, AMPKα1 siRNA and MTX; α2, AMPKα2 siRNA; α2M, AMPKα2 siRNA and
MTX; C, scrambled control siRNA; CM, control siRNA and MTX; CREB, CREB siRNA; CREB M, CREB siRNA and MTX; UT, untreated. *p<0.05;
**p<0.01; ***p<0.001.
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renal function at 30 weeks.32 However, the study used threefold
higher doses of MTX than stated herein, and this may have con-
tributed to mortality, given that MTX accumulates in renal
failure which is universal in older WBF1 mice. Treatment of
mice with early disease demonstrated that MTX reduces the
severity of the vasculopathy and attenuates organ damage. MTX
exerted speciﬁc anti-inﬂammatory actions, reducing aortic endo-
thelial and adventitial ICAM-1 and preventing leucocytic inﬁl-
tration of the arterial wall, suggesting an additional mechanism
by which MTX may retard CV events in RA. However, despite
the fact that MTX therapy activates protective pathways and
that basic pathogenic mechanisms of arterial injury in the WBF1
mice including immunoglobulin deposition, complement activa-
tion, focal leucocyte inﬁltration and endothelial damage are gen-
erally applicable across many systemic inﬂammatory diseases,
they do not necessarily translate to the situation in human RA.
Thus, further studies are now required in patients.
AMPK is associated with anti-inﬂammatory and desirable
metabolic changes in many different systems and disease set-
tings.1 33 Understanding of the relationship between AMPK,
endothelial dysfunction and atherogenesis remains incomplete.
However, current thinking suggests that reduced AMPK activity
predisposes to endothelial dysfunction, while AMPK activation
by laminar shear stress may contribute to vasculoprotection.20
Thus, our ﬁnding that MTX activates AMPK in human ECs
may provide an important mechanistic explanation for the clin-
ical observation of reduced CVD in patients with RA, prescribed
this drug.
The current study demonstrates AMPK phosphorylation and
induction of protective target genes using MTX concentrations
in vitro that are achievable in patient sera.22 Moreover, increased
phosphorylated AMPK and upregulation of the downstream
target MnSOD were identiﬁed in murine aortae following MTX
administration using a regimen analogous to the long-term,
low-dose therapy used for chronic inﬂammatory disease. This
strongly suggests that MTX-mediated AMPK activation is likely
to be a real phenomenon in patients. We have also reported that,
in vitro, the anti-inﬂammatory drug, celecoxib, can speciﬁcally
induce EC AMPK phosphorylation,34 while at supra-therapeutic
concentrations, metformin has a similar effect.6 Further investi-
gation is required to establish the extent to which these observa-
tions can be directly translated to patients.
Although we have yet to determine how MTX activates
AMPK, we speculate that this is secondary to increased
intracellular ZMP and AMP levels. ZMP and AMP bind to the
AMPKγ subunit, delaying dephosphorylation of Thr172 in the α
Figure 5 Manganese superoxide
dismutase (MnSOD) induction by
methotrexate (MTX) is not altered by
cotreatment with folic acid (FA) or by
pre-treatment with tumour necrosis
factor α (TNFα), and MTX protects
endothelial cells (EC) against apoptosis
induced by glucose deprivation.
(A) Human umbilical vein EC (HUVEC)
were treated with MTX 10 nM in the
presence and absence of FA 50 nM for
48 h. MnSOD mRNA was quantiﬁed by
qRT-PCR. (B) and (C) HUVECs were
pretreated with TNFα 1 ng/mL for 24 h
prior to MTX 10 nM for 48 h. Changes
in (B) MnSOD mRNA, and (C) haem
oxygenase-1 (HO-1) mRNA were
analysed by qRT-PCR. (D) HUVECs
were pretreated with MTX 100 nM for
54 h prior to glucose deprivation for
18 h, and measurement of apoptosis
using ﬂow-cytometric analysis of
Annexin V and propidium iodide
staining. (D) and (E) representative
Annexin V binding histograms with
pooled quantiﬁcation data, and (F) and
(G) propidium iodide staining and
quantiﬁcation. Black: HBSS alone;
white: glucose deprivation; grey: MTX
and glucose deprivation. Each
experiment was performed three to six
times. GD, glucose deprivation; H,
HBSS; M, MTX; T, TNFα; UT, untreated.
*p<0.05; **p<0.01.
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subunit. Exposure of EC to MTX resulted in delayed AMPK
phosphorylation, consistent with inhibition of AICAR transfor-
mylase and adenosine deaminase leading to accumulation of
ZMP and AMP. These enzymes are most potently inhibited by
MTX-polyglutamates, an important fact, given that MTX is
rapidly converted to MTX-polyglutamates, the erythrocyte con-
centrations of which are more closely associated with clinical
responses than MTX plasma levels.11 MTX is known to
increase AICAR levels in HUVECs after a 48 h treatment12 and
can enhance activation of AMPK by AICAR in cancer cell
lines.35 While this manuscript was under review, Pirkmajer et al
have shown that MTX and AICAR together increase ZMP in
cultured myotubes, supporting our hypothesis as to how MTX
activates AMPK.36
Previous studies have shown that the AMPKα1 isoform is
more abundant in ECs and have, therefore, focused on its
functional effects.6 23 Recent evidence suggests that important
vasculoprotective effects are also mediated through AMPKα2.5
Our study demonstrates that depletion of either α subunit attenu-
ates MTX-mediated MnSOD and HO-1 induction. For the regu-
lation of MnSOD, AMPKα2 activity seemed somewhat more
important than α1, a fact supported by the ﬁnding that addition
of SOD to aortae from AMPKα2−/− mice can rescue endothelial
dysfunction.5 Interestingly, the α2 subunit is thought to be the
more sensitive to AMP,37 and this is consistent with our specula-
tion that MTX activates AMPK by altering levels of AMP.
MTX treatment attenuated apoptosis induced by glucose
deprivation, a response replicated by the AMPK agonist
AICAR.4 The underlying mechanism is likely multifactorial.
AMPK activation moves cells away from glycolysis as an ATP
source, and promotes mitochondrial oxidative phosphorylation,
thus prolonging cell survival in low glucose conditions.
Figure 6 Treatment of WBF1 mice
with methotrexate (MTX) leads to
AMP-activated protein kinase α
(AMPKα) phosphorylation and
manganese superoxide dismutase
(MnSOD) induction in the aorta and
reduces intercellular adhesion molecule
(ICAM)-1 expression. Male WBF1 mice
were treated with MTX 1 mg/kg or an
equal volume of 0.9% saline (n=14 in
both groups) by intraperitoneal
injection weekly for 4 weeks from 12
to 16 weeks of age. After euthanasia
at 16 weeks, the descending aorta was
snap-frozen and lysed for
immunoblotting, or embedded upright
in optical cutting temperature
compound, and 10 μm transverse
sections cut. (A) and (B) representative
immunoblot and densitometry of aortic
AMPKαThr172 phosphorylation. (C) and
(D) representative immunoblot and
densitometry of aortic MnSOD. (E) and
(F) representative confocal images from
an animal treated with (E) 0.9% saline
and (F) MTX. EC, endothelium and Ad,
adventitia. Sections are stained with
anti-ICAM-1 (red), anti-CD31 as an
endothelial marker (green); and
DRAQ5 nuclear stain (purple). (G)
Quantiﬁcation of endothelial ICAM-1
staining. (H) Quantiﬁcation of
adventitial ICAM-1 staining. Data are
expressed as mean ﬂuorescence
intensity (MFI). M, individual
MTX-treated animal; C, individual
control animal treated with 0.9%
saline; *p<0.05; **p<0.01.
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Additionally, induction of A1 and HO-1 by MTX may exert
antiapoptotic effects. MnSOD, UCP-2 and HO-1 induction will
also impart important antioxidant effects which improve cell
survival. Although beyond the scope of this initial report, induc-
tion of additional AMPK targets A1, UCP-2 and DAF suggest
that a whole-genome approach is now indicated to identify the
full extent of the cytoprotective proﬁle of MTX and to deter-
mine how its actions may be replicated by novel, more speciﬁc
compounds.
The demonstration that MTX activates an AMPK/
CREB-dependent signalling pathway to induce MnSOD and
HO-1 reveals signiﬁcant atheroprotective potential. MnSOD
induction protects against atherogenesis, and ApoE−/− mice deﬁ-
cient in MnSOD exhibit accelerated atherosclerosis.21 Recent
evidence points towards a central role for CREB in the mainten-
ance of a healthy arterial wall. Loss of aortic CREB is found in
rodent models of hypertension, atherosclerosis and insulin
resistance,25 while murine cardiac-speciﬁc expression of
dominant-negative CREB increases oxidative stress, mitochon-
drial dysfunction and mortality.38 Although CREBSer133 is a
direct target of AMPK,24 CREB activation by MTX might also
occur via adenosine binding of G protein-coupled receptors,
leading to protein kinase A activation via cAMP. However, this
well-described mechanism of CREB activation39 is thought only
to occur on promoters where the CRE site is within 250 bp of
the TATA box.40 The SOD2 promoter does not contain a TATA
box,41 and the CRE site likely to be responsible for the effects
of CREB binding presented here lies 1200 bp distal to the tran-
scription start site. This favours AMPK activation rather than
adenosine as the route to CREB activation by MTX.
The lack of evidence demonstrating a requirement for
AMPK-CREB signalling for the protective effects of MTX in
vivo is a limitation of this study. Their complex genetic back-
ground and the need to generate F1 animals to develop vasculo-
pathy precludes crossing WBF1 mice with an AMPK-deﬁcient
strain. Likewise, data obtained by treating animals daily with the
AMPK antagonist, Compound C, would be confounded by the
observation that the drug itself induces protective enzymes
including HO-1 and MnSOD.42 However, AMPKα activation
and MnSOD induction were demonstrated in aortae from
MTX-treated animals, suggesting they play a role in vascular
protection. Nevertheless, increased adenosine may also contrib-
ute to the vascular effects of MTX. Adenosine reduces cytokine-
mediated cell adhesion molecule upregulation in EC,43 and
MTX treatment promotes vasodilatory responses attributed to
ligation of adenosine 2A receptors.44
In conclusion, we have presented evidence for a novel MTX
mechanism of action in the vasculature, which identiﬁes speciﬁc
effects of low-dose MTX and moves the perception of this drug
from toxic to protective. We propose that low-dose MTX thera-
peutically conditions vascular endothelium via activation of
AMPK-CREB signalling, so inducing cytoprotective genes which
may contribute to the efﬁcacy of MTX in reducing CV compli-
cations in patients with RA.
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